Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Hoechst Marion Roussel Amaryl Sales Reach $62 Mil. In Second Quarter

  • News

Executive Summary

Worldwide sales of Hoechst Marion Roussel's Amaryl sulfonylurea treatment for type 2 diabetes increased by 77% in the second quarter to $62 mil. (EURO 58 mil.), the company reported in an Aug. 4 statement on financial results.

You may also be interested in...



Aventis Insuman Fourth Quarter NDA Planned After Manufacturing Changes

Aventis Pharma is targeting a fourth quarter NDA filing for its Insuman recombinant human insulin family after undergoing some changes in the manufacturing process of the compound.

Aventis Insuman Fourth Quarter NDA Planned After Manufacturing Changes

Aventis Pharma is targeting a fourth quarter NDA filing for its Insuman recombinant human insulin family after undergoing some changes in the manufacturing process of the compound.

HMR Expands Vertex Deal; Gains U.S. Rights To Arthritis Compound

Hoechst Marion Roussel is expanding its development deal with Vertex for the anti-inflammatory agent HMR 3480/VX-740 to include U.S. marketing rights, the firms said Sept. 1.

Table

View full table

Tags:
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS034634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By